Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04394624
Title Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (CARMEN-LC04)
Acronym CARMEN-LC04
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sanofi
Age Groups: adult | senior
Covered Countries USA | ESP

No variant requirements are available.